2-碘-5-羟基吡啶 | 129034-38-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-碘-5-羟基吡啶
• 中文别名: 6-碘吡啶-3-醇
• 英文名称: 6-iodopyridin-3-ol
• 英文别名: 5-hydroxy-2-iodopyridine
• CAS: 129034-38-4
• 化学式: C₅H₄INO
• mdl: MFCD09260905
• 分子量: 220.997
• InChiKey: UVNPCRNIHOCXEA-UHFFFAOYSA-N

物化性质

• 熔点：
  149-151 °C
• 沸点：
  399.7±27.0 °C(Predicted)
• 密度：
  2.142±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319

反应信息

• 作为反应物：
  描述：

  2-碘-5-羟基吡啶 在 4-二甲氨基吡啶 、 palladium diacetate 、 氢氧化钾 、 四丁基氯化铵 、 氢溴酸 、 sodium methylate 、 sodium hydride 、 potassium carbonate 、 N,N'-二环己基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 40.92h， 生成
  参考文献：
  名称：

  New Water-Soluble Duocarmycin Derivatives: Synthesis and Antitumor Activity of A-Ring Pyrrole Compounds Bearing β-Heteroarylacryloyl Groups

  摘要：

  A series of A-ring pyrrole compounds of duocarmycin bearing 4'-methoxy-beta-heteroarylacryloyl groups were synthesized and evaluated for in vitro anticellular activity against HeLa S-3 cells and in vivo antitumor activity against murine sarcoma 180 in mice. Most of the Li 4'-methoxy-beta-heteroarylacrylates displayed in vitro anticellular activity equivalent to that of 4'-methoxycinnamates, Among the 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxy-beta-heteroarylacrylates, compound 15b having a (4-methoxy-3,5-pyrimidinyl)acryloyl as segment-B (Seg-B) showed remarkably potent in vivo antitumor activity and low peripheral blood toxicity compared with the A-ring pyrrole derivatives having the trimethoxyindole skeleton in Seg-B, which were equal to 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxycinnamates. Moreover, these 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxy-beta-heteroarylacrylates had high aqueous solubility.

  DOI：

  10.1021/jm980559y
• 作为产物：
  描述：

  3-羟基吡啶 在 盐酸 、 sodium hydroxide 、 sodium hypochlorite 、 sodium iodide 、 sodium chloride 、 sodium thiosulfate 作用下， 以 甲醇 为溶剂， 以34%的产率得到2-碘-5-羟基吡啶
  参考文献：
  名称：

  DC-89 derivatives

  摘要：

  提供了由以下公式表示的DC-89衍生物：##STR1## 其中，X代表Cl或Br，R代表氢或COR.sup.1，W代表##STR2##以及其药学上可接受的盐。本发明化合物具有优异的抗肿瘤活性，可用作抗肿瘤剂。

  公开号：

  US05670492A1

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• [EN] UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY<br/>[FR] INHIBITEURS DE L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA) À BASE D'URÉE, POUR IMAGERIE ET TRAITEMENT THÉRAPEUTIQUE
  申请人：FIVE ELEVEN PHARMA INC

  公开号：WO2017116994A1

  公开（公告）日：2017-07-06

  The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.

  本发明涉及符合式I和符合式IV的化合物。这些化合物显示出非常好的结合亲和力，能与PSMA结合位点结合。它们可以用[68Ga]GaCl3标记，产率高，放射化学纯度优秀。本发明还涉及包含药用可接受载体和符合式I或符合式IV的化合物，或其药用可接受盐的药物组合物。
• Compounds and compositions as anticoagulants
  申请人：Axys Pharmaceuticals, Inc.

  公开号：US06150379A1

  公开（公告）日：2000-11-21

  The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新的双杂环衍生物，它们是Xa因子抑制剂；其药用盐和N-氧化物；它们作为治疗剂的用途以及其制备方法。
• Novel Compounds Derived From 5-Thioxylose And Their Use In Therapeutics
  申请人：Barberousse Veronique

  公开号：US20080293768A1

  公开（公告）日：2008-11-27

  The invention relates to novel 5-thioxylose compounds, preferably derivatives of the 5-thioxylopyranose type, to the process for their preparation and to their use as active principles of drugs intended especially for the treatment or prevention of thrombosis or cardiac insufficiency.

  这项发明涉及新颖的5-硫木糖化合物，优选为5-硫木糖吡喃糖类衍生物，以及它们的制备过程和它们作为药物活性成分的用途，主要用于治疗或预防血栓形成或心脏功能不全。